179 related articles for article (PubMed ID: 12516965)
1. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
[TBL] [Abstract][Full Text] [Related]
2. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
Mensah-Osman EJ; Al-Katib AM; Dandashi MH; Mohammad RM
Mol Cancer Ther; 2002 Dec; 1(14):1315-20. PubMed ID: 12516964
[TBL] [Abstract][Full Text] [Related]
3. XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.
Mensah-Osman E; Al-Katib A; Dandashi M; Mohammad R
Int J Oncol; 2003 Dec; 23(6):1637-44. PubMed ID: 14612935
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model.
Mensah-Osman EJ; Al-Katib AM; Mohammad RM
Clin Cancer Res; 2003 Nov; 9(15):5794-7. PubMed ID: 14654565
[TBL] [Abstract][Full Text] [Related]
5. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
6. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
7. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
[TBL] [Abstract][Full Text] [Related]
9. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
Gao H; Yamasaki EF; Chan KK; Shen LL; Snapka RM
Mol Pharmacol; 2003 Jun; 63(6):1382-8. PubMed ID: 12761349
[TBL] [Abstract][Full Text] [Related]
10. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
11. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of G2/M cycle arrest induced by topo IIalpha and II beta inhibitors in H460 cells].
Ling ZH; Ding ZH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2187-90. PubMed ID: 19114353
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting.
Padget K; Pearson AD; Austin CA
Leukemia; 2000 Nov; 14(11):1997-2005. PubMed ID: 11069037
[TBL] [Abstract][Full Text] [Related]
14. XK469, a selective topoisomerase IIbeta poison.
Gao H; Huang KC; Yamasaki EF; Chan KK; Chohan L; Snapka RM
Proc Natl Acad Sci U S A; 1999 Oct; 96(21):12168-73. PubMed ID: 10518594
[TBL] [Abstract][Full Text] [Related]
15. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
16. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
17. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
18. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
19. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.
Willmore E; Frank AJ; Padget K; Tilby MJ; Austin CA
Mol Pharmacol; 1998 Jul; 54(1):78-85. PubMed ID: 9658192
[TBL] [Abstract][Full Text] [Related]
20. Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIalpha/beta poison.
Gao H; Yamasaki EF; Chan KK; Shen LL; Snapka RM
Cancer Res; 2000 Nov; 60(21):5937-40. PubMed ID: 11085507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
